{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:18Z","timestamp":1790375358231,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00277-018-3413-7","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:05:43Z","timestamp":1530144343000},"page":"2089-2098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?"],"prefix":"10.1007","volume":"97","author":[{"name":"On behalf of the CML Spanish Group (GELMC)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-0490","authenticated-orcid":false,"given":"Santiago","family":"Osorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"G\u00f3mez-Centuri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferr\u00e1n","family":"Vall-Llovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 David","family":"Gonz\u00e1lez San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-\u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn","family":"S\u00e1nchez-Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Villal\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venancio","family":"Conesa-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xandra","family":"Garcia-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Nieves","family":"S\u00e1ez Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00darsula","family":"Ba\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"issue":"6","key":"3413_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"24","key":"3413_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, TM-L A (2016 Aug 20) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857","journal-title":"J Clin Oncol"},{"issue":"22","key":"3413_CR3","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde M-A, De Bock R, Verhoef G, Zach\u00e9e P, Berneman Z et al (2009 May 28) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401\u20135411","journal-title":"Blood"},{"issue":"8","key":"3413_CR4","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"A Haouala","year":"2011","unstructured":"Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA (2011 24 Feb) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8):e75\u2013e87","journal-title":"Blood"},{"issue":"24","key":"3413_CR5","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J (2009 Dec 15) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15(24):7519\u20137527","journal-title":"Clin Cancer Res"},{"issue":"40","key":"3413_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005076","volume":"95","author":"I R\u00e9coch\u00e9","year":"2016","unstructured":"R\u00e9coch\u00e9 I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E (2016 Oct) Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore) 95(40):e5076","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3413_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.mayocp.2012.10.020","volume":"88","author":"SJ Bowlin","year":"2013","unstructured":"Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ (2013 Feb) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 88(2):139\u2013148","journal-title":"Mayo Clin Proc"},{"key":"3413_CR8","unstructured":"Lexicomp. Drugs interactions. Wolters Kluwer Clinical Drug Information, Inc., 2017. \n                    www.lexi.com\/online\n                    \n                   (accessed 17 July 2017)"},{"key":"3413_CR9","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Bethesda, Md. U.S. Department of Health and Human Services, National Institutes of Health, 2010. National Cancer Institute"},{"issue":"4","key":"3413_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan L-N (2007 Apr) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 41(4):674\u2013680","journal-title":"Ann Pharmacother"},{"key":"3413_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/1471-2407-10-679","volume":"10","author":"RWF Leeuwen van","year":"2010","unstructured":"van Leeuwen RWF, Swart EL, Boom FA, Schuitenmaker MS, Hugtenburg JG (2010 Dec 13) Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer 10:679","journal-title":"BMC Cancer"},{"issue":"5","key":"3413_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00520-010-0813-1","volume":"18","author":"J Cashman","year":"2010","unstructured":"Cashman J, Wright J, Ring A (2010 May) The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer 18(5):651\u2013655","journal-title":"Support Care Cancer"},{"issue":"6","key":"3413_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1080\/10428194.2016.1251592","volume":"58","author":"HD Finnes","year":"2017","unstructured":"Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA (2017 Jun) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58(6):1376\u20131383","journal-title":"Leuk Lymphoma"},{"key":"3413_CR14","unstructured":"European Public Assessment Reports. Imatinib, nilotinib, dasatinib. London: European Medicines Agency. Available at: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search. jsp&mid=WC0b01ac058001d124\n                    \n                   [Accessed in January 2018]"},{"issue":"11","key":"3413_CR15","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1021\/mp400403s","volume":"10","author":"GS Smelick","year":"2013","unstructured":"Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL et al (2013 Nov 4) Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 10(11):4055\u20134062","journal-title":"Mol Pharm"},{"issue":"7","key":"3413_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","volume":"56","author":"RWF Leeuwen van","year":"2017","unstructured":"van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ (2017) Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options. Clin Pharmacokinet 56(7):683\u2013688","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3413_CR17","first-page":"81","volume":"96","author":"F Cervantes","year":"2017","unstructured":"Cervantes F, Correa JG, P\u00e9rez I, Garc\u00eda-Guti\u00e9rrez V, Redondo S, Colomer D et al (2017) Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Jan 96(1):81\u201385","journal-title":"Jan"},{"issue":"6","key":"3413_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/138920011795713706","volume":"12","author":"F Caraci","year":"2011","unstructured":"Caraci F, Crupi R, Drago F, Spina E (2011 Jul) Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 12(6):570\u2013577","journal-title":"Curr Drug Metab"},{"issue":"11","key":"3413_CR19","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/bjc.2012.173","volume":"106","author":"J Wang","year":"2012","unstructured":"Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D\u2019Andrea RJ, White DL (2012 May 22) Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. Br J Cancer 106(11):1772\u20131778","journal-title":"Br J Cancer"},{"key":"3413_CR20","unstructured":"Osorio S, Escudero-Vilaplana V, Reguil\u00f3n-Gallego L, G\u00f3mez-Centuri\u00f3n I, D\u00edez JL, Ferrer-Mar\u00edn F (2017) Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline. J Oncol Pharm Pract 1078155217735689"},{"issue":"6","key":"3413_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00228-016-2038-9","volume":"72","author":"F Atiq","year":"2016","unstructured":"Atiq F, Broers AEC, Andrews LM, Doorduijn JK, Koch BCP, Van Gelder T et al (2016 Jun) A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. Eur J Clin Pharmacol 72(6):719\u2013723","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3413_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/bcp.12584","volume":"80","author":"D Renard","year":"2015","unstructured":"Renard D, Bouillon T, Zhou P, Flesch G, Quinn D (2015 Jul) Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. Br J Clin Pharmacol 80(1):75\u201385","journal-title":"Br J Clin Pharmacol"},{"key":"3413_CR23","unstructured":"Osorio S, Escudero-Vilaplana V, G\u00f3mez-Centuri\u00f3n I, Gonz\u00e1lez-Arias E, Garc\u00eda-Gonz\u00e1lez X, D\u00edez JL (2017) Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin. J Oncol Pharm Pract 1078155217743565"},{"issue":"4","key":"3413_CR24","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/ped.12382","volume":"56","author":"K Taguchi","year":"2014","unstructured":"Taguchi K, Kouroki M, Ohmura T, Jono H, Endo F, Saito H (2014 Aug) Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia. Pediatr Int 56(4):e33\u2013e36","journal-title":"Pediatr Int"},{"issue":"3","key":"3413_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2174\/157488408785747656","volume":"3","author":"S Pursche","year":"2008","unstructured":"Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R et al (2008 Sep) Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 3(3):198\u2013203","journal-title":"Curr Clin Pharmacol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3413-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T19:24:27Z","timestamp":1561663467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3413-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3413"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3413-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"8 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This collaborative study was performed in 15 centers within the framework of the Spanish CML Group. It was approved by the Spanish Drug Agency, and the institutional Research Ethics Committees. All procedures followed were in accordance with the ethical standards of these national and institutional Committees, and with the Helsinki Declaration of 1975, as revised in 2008. Due to the retrospective nature of the study, with no interventions, formal informed consent was not considered necessary by the aforementioned Committees for approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}